Skip to main content
Oncoinvent ASA logo

Oncoinvent ASA — Investor Relations & Filings

Ticker · OCIN ISIN · NO0010779341 LEI · 54930076H5GUZRMSNR39 Euronext Growth Manufacturing
Open in API
Filings indexed 138 across all filing types
Latest filing 2025-12-02 Director's Dealing
Country NO Norway
Listing Euronext Growth OCIN

About Oncoinvent ASA

https://www.oncoinvent.com/

Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.

Recent filings

Filing Released Lang Actions
Oncoinvent ASA: Notification of trade - primary insider/close associate
Director's Dealing Classification · 100% confidence The document is a notification of trade by primary insiders and their close associates regarding the allocation of new shares in a rights issue. It explicitly lists the names of board members and executives and the number of shares they have been allocated. This falls under the category of Director's Dealing (DIRS), as it reports personal share transactions/allocations by company insiders.
2025-12-02 English
Oncoinvent ASA: Final results of the rights issue
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Oncoinvent ASA regarding the final results of a rights issue, including details on subscription numbers, allocation, and expected trading dates. This falls under the category of capital structure changes and share issuance. While it discusses a rights issue, it is an announcement of the results rather than a prospectus or a general regulatory filing, making 'SHA' (Share Issue/Capital Change) the most accurate classification.
2025-12-02 English
Oncoinvent ASA: Preliminary results of the rights issue
Capital/Financing Update Classification · 100% confidence The document is an official announcement from Oncoinvent ASA regarding the preliminary results of a rights issue (a capital raising activity). It details the subscription period expiration, the number of shares subscribed, and the timeline for final allocation. This falls under the category of capital and financing updates, as it pertains to the company's capital structure and fundraising efforts.
2025-12-01 English
Oncoinvent ASA: Last day of the subscription period in the rights issue
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the final day of a subscription period for a rights issue (a capital raising event). It provides details on the deadline, how to subscribe, and references the previously published prospectus. It does not contain the prospectus itself, but rather serves as a notice to investors regarding the ongoing financing activity. Therefore, it falls under the 'Capital/Financing Update' category.
2025-12-01 English
Oncoinvent ASA: Notification of trade - primary insider/close associate - Attachment: 2025_11_27_PDMR_Attachment_exercise_of_subscription_rights.pdf
Director's Dealing Classification · 100% confidence The document is a standard regulatory notification form detailing transactions by persons discharging managerial responsibilities (PDMRs) and their closely associated persons. It explicitly lists names, positions (e.g., chairperson of the board), nature of transactions (subscription of shares), and transaction details (price, volume, date). This format is characteristic of a Director's Dealing or PDMR notification, which falls under the 'DIRS' category.
2025-11-27 English
Oncoinvent ASA: Notification of trade - primary insider/close associate - Attachment: 2025_11_27_Notification_of_trade_primary_insiders.pdf
Share Issue/Capital Change Classification · 100% confidence The document is a notification of trade by primary insiders and their close associates regarding the exercise of subscription rights in a rights issue. While it mentions a rights issue, the core purpose of the document is to report specific share transactions by company directors and executives, which falls under the 'Director's Dealing' category. It explicitly references the EU Market Abuse Regulation (MAR) disclosure requirements for insider trades.
2025-11-27 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.